Tag Archives: from

GBT takes a page from HIV playbook as it embarks on Oxbryta launch

The sickle cell disease market and patient support around the disease are both in the nascent stages. But Global Blood Therapeutics, a pioneer in the field with recently approved Oxbryta, sees an example to emulate as it embarks on its first launch: HIV. In sickle cell, “there’s been tremendous underinvestment—underinvestment in the science, obviously underinvestment… Read More »

‘Nobody cares about me’ Canadian stuck in Wuhan received little help from Global Affairs

As scores of his compatriots climbed off an evacuation flight from Wuhan, China, on Friday, Qi (Kevin) Jin was still languishing at ground zero of the coronavirus outbreak — and feeling decidedly abandoned. The Canadian citizen based in Toronto says he has registered repeatedly with Global Affairs Canada, but heard next to nothing from the department… Read More »

Can an N95 face mask protect you from catching the new coronavirus?

By Jessica Hamzelou A man wears a mask near Wuhan, ChinaStringer/Getty Face masks are reportedly selling out in cities across Asia as concerns over the spread of a deadly new coronavirus grow. China’s National Health Commission has deployed masks to healthcare workers responding to the outbreak, and millions of masks have been sent to residents… Read More »

China’s Vast Ambition in Medicine Gets Reality Check From Coronavirus – The Wall Street Journal

By Betsy McKay, Betsy McKay The Wall Street Journal Biography @betswrites Betsy.McKay@wsj.com James T. Areddy and James T. Areddy The Wall Street Journal Biography @jamestareddy jamestareddy James.Areddy@wsj.com Chao Deng Chao Deng The Wall Street Journal Biography @chao_deng chao.deng@wsj.com Updated Jan. 24, 2020 11:28 pm ET Medical staff in Wuhan transfer patients to a hospital on… Read More »

Pfizer challenges Roche blockbusters with 3 biosim launches at discounts from 22% to 24%

Pfizer hit some unexpected roadblocks with its first U.S. biosimilar launch, but it’s not giving up in the budding field. Now, the drugmaker is launching biosims to three Roche cancer blockbusters at discounts ranging from 22% to 24%.   The company has already rolled out Zirabev and Ruxience, its biosimilars to Roche’s Avastin and Rituxan, respectively, at discounts of 23% and 24%. On… Read More »